The Motion: Radical Cystectomy in the Elderly is Becoming a Standard Treatment for Bladder Cancer

2007 ◽  
Vol 51 (5) ◽  
pp. 1435-1438 ◽  
Urology ◽  
2015 ◽  
Vol 85 (4) ◽  
pp. 791-798 ◽  
Author(s):  
Michael J. Leveridge ◽  
D. Robert Siemens ◽  
William J. Mackillop ◽  
Yingwei Peng ◽  
Ian F. Tannock ◽  
...  

2014 ◽  
Vol 86 (4) ◽  
pp. 295
Author(s):  
Salih Budak ◽  
Hüseyin Aydemir ◽  
Hasan Salih Saglam ◽  
Oztug Adsan

The current standard treatment for nonmetastatic invasive bladder cancer is radical cystectomy with urinary diversion. Radical cystectomy surgery carries a serious potential risk of complications. In this case report, an intestinal perforation which was thought to be occurred due to a Foley catheter placed as a drain after the cystectomy is presented.


2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Matthew Raynor ◽  
Stephen McKim ◽  
Eugene Simopoulos ◽  
Matthew Nielsen ◽  
Eric Wallen ◽  
...  

2009 ◽  
Vol 56 (3) ◽  
pp. 443-454 ◽  
Author(s):  
Michael Froehner ◽  
Maurizio A. Brausi ◽  
Harry W. Herr ◽  
Giovanni Muto ◽  
Urs E. Studer

2012 ◽  
Vol 26 (10) ◽  
pp. 1301-1306 ◽  
Author(s):  
Kyle A. Richards ◽  
A. Karim Kader ◽  
Rick Otto ◽  
Joseph A. Pettus ◽  
John J. Smith ◽  
...  

2009 ◽  
Vol 181 (4S) ◽  
pp. 363-363
Author(s):  
Jeff Nix ◽  
Matthew Coward ◽  
Angela Smith ◽  
Raj Kurpad ◽  
Matthew Nielsen ◽  
...  

2013 ◽  
Vol 2 (2) ◽  
pp. 102 ◽  
Author(s):  
Nader Fahmy ◽  
Wassim Kassouf ◽  
Suganthiny Jeyaganth ◽  
Moamen Amin ◽  
Salaheddin Mahmud ◽  
...  

Background: The province of Quebec has the highest incidence of urothelialtumours in Canada. Radical cystectomy remains the standard treatment for invasivebladder cancer. We have previously observed that prolonged delays betweentransurethral resection of bladder tumour (TURBT) and radical cystectomy leadto worse survival in Quebec.Objective: The aim of our study was to characterize the various periods of delaysustained by bladder cancer patients before radical cystectomy across Quebecand to determine their relation to survival.Methods: We obtained the billing records for all patients treated with radicalcystectomies for bladder cancer across Quebec from 1990 to 2002. Collectedinformation included patient age and sex; dates of family physician (FP) andspecialist visits with accompanying diagnoses; dates of cystoscopy, TURBT andCT scanning; surgeon age; surgical volume and dates of death.Results: We analyzed a total of 25 862 visits for 1633 patients. Median diagnosticdelays from FP to specialist, then to cystoscopy, then to TURBT and finallyfrom TURBT to CT were 20, 11, 4 and 14 days, respectively, over the entirestudy period. Median overall delay from FP visit to radical cystectomy was93 days. In addition, median FP to radical cystectomy delay progressivelyincreased from 1990 to 2000 from 58 to 120 days (p < 0.01). Multivariate analysesshowed that patients with an overall delay of either < 25 or > 84 dayshad a 2.1 and 1.4 times increased risk of dying, respectively (p ≤ 0.01).Conclusion: Preoperative delays have been progressively increasing over time.Overall, delays from FP to radical cystectomy of < 25 and > 84 days may translateinto worse outcomes. Poor survival in cases with < 25 days delay maybe attributed to case selection, with more advanced cases being managed muchquicker. Poor survival in cases with delays of > 84 days may be attributed todisease progression while awaiting completion of management.


2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 248-248 ◽  
Author(s):  
Phillip J. Gray ◽  
Stacey A. Fedewa ◽  
William U. Shipley ◽  
Chun Chieh Lin ◽  
Katherine S. Virgo ◽  
...  

248 Background: Radical cystectomy (RC) is the most common treatment for bladder cancer (BC) in the United States. We examined clinical-pathologic stage discrepancy using the National Cancer Data Base. Methods: 16,953 patients with BC treated with RC between 1998 and 2009 were analyzed. Clinical factors associated with stage discrepancy were assessed by multivariable generalized estimating equation models. Survival analysis was conducted for patients treated between 1998 and 2004 (N=7,270) using a Cox proportional hazards model. Results: 41.9% of patients were upstaged at RC while 5.9% were downstaged. Upstaging was more common in females (OR 1.08, p=.04), the elderly (OR 1.26 for age ≥80 vs. 18-59, p=.001), higher tumor grade (OR 2.29 for grade 3-4 vs. grade 1, p<.0001), non-urothelial histology (OR 1.31, p=.002 for squamous and OR 1.26, p=.03 for adenocarcinoma), and with extended lymphadenectomy (OR 1.27 for ≥10 lymph nodes examined vs. 0-9, p<.0001). Downstaging was less common in the elderly (OR 0.50 for age ≥80 vs. 18-59, p<.0001), in Hispanics (OR 0.58, p=.009) and with variant histology (OR 0.55, p=.003 for squamous and OR 0.3, p<.0001 for adenocarcinoma). Receipt of neoadjuvant chemotherapy (CT) was highly associated with downstaging (OR 2.31, p<.0001). 5-year survival by stage is shown in the table. Upstaging was associated with increased 5-year mortality (HR 1.79, p<.0001) as was receipt of CT (HR 1.28, p=.02 for neoadjuvant and HR 1.23, p<.0001 for adjuvant). Extended lymphadenectomy was associated with decreased 5-year mortality (HR 0.82 for ≥10 lymph nodes examined vs. 0-9, p<.0001). Downstaging was not associated with survival (HR 0.88, p=0.17). Conclusions: This study is the largest to date to analyze stage discrepancy and survival in BC patients treated with RC. Upstaging is common and is associated with decreased 5-year survival. These data can be used in pre-operative risk stratification, treatment decision making and comparison with studies of non-operative management. [Table: see text]


2007 ◽  
Vol 177 (4S) ◽  
pp. 79-80
Author(s):  
Jose A. Karam ◽  
Yair Lotan ◽  
Raheela Ashfaq ◽  
Claus G. Roehrborn ◽  
Arthur I. Sagalowsky ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document